Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2025-11-12 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic - Expédition - 30.10.2025.pdf
AGM Information Classification · 98% confidence The document is a 'Procès-verbal de carence' (Minutes of Deficiency) for an Extraordinary General Meeting of the company 'BioSenic'. It details that the required quorum for the meeting was not met, and therefore no resolutions could be passed, necessitating a second meeting. This document serves as the official record of the meeting proceedings and the failure to reach a quorum, which falls under the category of AGM-related materials (AGM-R).
2025-11-12 French
BioSenic - Expédition - 30.10.2025.pdf
AGM Information Classification · 98% confidence The document is a 'Procès-verbal de carence' (Minutes of Deficiency) for an Extraordinary General Meeting of the company 'BioSenic'. It details that the required quorum for the meeting was not met, and therefore no resolutions could be passed, necessitating a second meeting. This document serves as the official record of the meeting proceedings and the failure to reach a quorum, which falls under the category of AGM-related materials (AGM-R).
2025-11-12 French
BIOS_H1-PR Report_FR_2025 10 28_final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2025 (interim period), titled 'BioSenic publie ses résultats pour le premier semestre 2025'. It contains substantive financial data, including an 'Etat intermédiaire condensé non audité du résultat global' (Income Statement), 'État de la situation financière intermédiaire résumé non audité' (Balance Sheet), and 'Tableau des flux de trésorerie' (Cash Flow Statement). It is not merely an announcement, as it provides detailed financial tables and management commentary on business trends and outlook, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-10-28 French
549300HFIIMTOP1DFR76-2024-12-31-0-fr.xhtml
Annual Report
2025-09-29 French
549300HFIIMTOP1DFR76-2024-12-31-0-fr.zip
Annual Report (ESEF)
2025-09-29 French
BioSenic SA_ Information on shareholders' rights GMs_FR_2025 09 29.pdf
AGM Information Classification · 98% confidence The document is a formal notice to shareholders regarding their rights to add items to the agenda and submit written questions for the upcoming Annual General and Extraordinary Meetings of BioSenic. It references specific articles of the Belgian Code of Companies and Associations (7:130 and 7:139). This type of document is a standard proxy-related communication sent to shareholders to facilitate their participation in the voting process and meeting governance, which falls under the Proxy Solicitation & Information Statement category.
2025-09-29 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.